Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

LAKE LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

The Schall Law Firm Wants Investors To Participate In A Securities Fraud Case Against Moderna, Inc.

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME Therapeutics aims to enhance the precision and efficacy of myeloid cell-delivered mRNA therapeutics in vivo to develop potential new cancer therapies by leveraging the cutting-edge lipid nanoparticle (LNP) technologies of NanoVation Therapeutics.

ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

RIO RANCHO, N.M.--(BUSINESS WIRE)--NTx's new services offering provides faster and more affordable high-integrity, complex mRNA production powered by NTxscribe®.

NTx Services Launches to Supercharge Next Generation mRNA Research

NEW YORK CITY, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").

MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Viking Therapeutics

Vertex Pharmaceuticals

Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Moderna (MRNA) shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine.

Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the “Class Period”), of the important October 8, 2024 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

Moderna Inc Is Being Sued For Possible Securities Law Violations And Affected Shareholders Should Contact The Schall Law Firm

SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season. Moderna will promptly begin delivery of updated COVID-19 vaccines to the Public Health Agency of Canada, so there is robust supply available in time for provincial and territorial vaccination campaigns.

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

NEW YORK CITY, NY / ACCESSWIRE / September 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").

MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=103067&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Moderna, Inc.(MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit.

Lost Money on Moderna, Inc. (MRNA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

The Schall Law Firm Urges Investors With Losses In Moderna, Inc. To Join A Securities Fraud Case

Moderna Inc. NASDAQ: MRNA made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. mRNA vaccines deliver a virus's blueprints or genetic instructions to the cells to trigger the immune system to make antibodies to protect against it.

Moderna's Recent Drop: 4 Reasons Bulls See Opportunity

NEW YORK CITY, NY / ACCESSWIRE / September 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").

MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

Moderna Inc Is Being Sued For Violating Securities Laws And Stakeholders Are Invited By The Schall Law Firm To Play A Part

Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget.

Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?

NEW YORK CITY, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").

MRNA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Apple

Eli Lilly

Microsoft

Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna

NEW YORK, NY / ACCESSWIRE / September 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=102642&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

The Schall Law Firm Wants Investors To Assist The Schall Law Firm In A Securities Fraud Case Against Moderna, Inc.

AbbVie

Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.

Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the “Class Period”), of the important October 8, 2024 lead plaintiff deadline.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

Moderna's shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some changes to its strategy -- and a key goal.

After Moderna's Shocking News, Is the Stock a Buy or a Sell?

Thursday, Moderna Inc MRNA unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.

News for Moderna Stock (MRNA)